Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
49
BCAX Quote, Financials, Valuation and Earnings
Last price:
$21.43
Seasonality move
:
-23.95%
Day range:
$19.92 - $21.50
52-week range:
$7.80 - $21.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.50x
Volume:
919.8K
Avg. volume:
669.6K
1-year change:
61.92%
Market cap:
$1.5B
Revenue:
--
EPS (TTM):
-$2.23
Analysts' Opinion
-
Consensus RatingBicara Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.50, Bicara Therapeutics, Inc. has an estimated upside of 42.06% from its current price of $21.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 25.48% downside risk from its current price of $21.47.
Fair Value
-
According to the consensus of 11 analysts, Bicara Therapeutics, Inc. has 42.06% upside to fair value with a price target of $30.50 per share.
BCAX vs. S&P 500
-
Over the past 5 trading days, Bicara Therapeutics, Inc. has overperformed the S&P 500 by 9.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bicara Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bicara Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bicara Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Bicara Therapeutics, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Bicara Therapeutics, Inc. reported earnings per share of -$0.67.
Enterprise value:
992.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-9.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$77K
Return On Assets:
-24.8%
Net Income Margin (TTM):
--
Return On Equity:
-26.44%
Return On Invested Capital:
-26.37%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$16K | -$56K | -$105K | -$15K | -$43K | |
| Operating Income | -$39.9M | -$82.4M | -$155.6M | -$26.6M | -$41.1M | |
| EBITDA | -$52M | -$82.3M | -$155.5M | -$26.6M | -$41.1M | |
| Diluted EPS | -$0.65 | -$1.25 | -$2.52 | -$0.39 | -$0.68 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $231.1M | $502.5M | $422.1M | |
| Total Assets | -- | -- | $234M | $569.2M | $529.3M | |
| Current Liabilities | -- | -- | $15.1M | $18M | $28.9M | |
| Total Liabilities | -- | -- | $15.5M | $77.3M | $127.8M | |
| Total Equity | -- | -- | $218.5M | $491.9M | $401.5M | |
| Total Debt | -- | -- | $372K | $131K | $593K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$45.6M | -$74.8M | -$106.8M | -$30M | -$23.9M | |
| Cash From Investing | -$586K | -$9K | -$318.5M | -$40K | -$82.3M | |
| Cash From Financing | $272.5M | $334M | $32.3M | -$975K | $31.2M | |
| Free Cash Flow | -$45.6M | -$74.8M | -$107.1M | -$30.1M | -$24.1M | |
BCAX
Sector
Market Cap
$1.5B
$23.9M
Price % of 52-Week High
99.86%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.04%
-1.9%
1-Year Price Total Return
61.92%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.38
200-day SMA
Buy
Level
$14.92
Bollinger Bands (100)
Buy
Level
15.65 - 18.89
Chaikin Money Flow
Sell
Level
-4.5M
20-day SMA
Buy
Level
$19.21
Relative Strength Index (RSI14)
Buy
Level
71.54
ADX Line
Buy
Level
15.1
Williams %R
Sell
Level
-0.7752
50-day SMA
Buy
Level
$17.43
MACD (12, 26)
Buy
Level
0.73
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
5.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4423)
Sell
CA Score
(Annual)
Level (-0.305)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.5978)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, BCAX has received 8 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BCAX average analyst price target in the past 3 months is $30.50.
-
Where Will Bicara Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bicara Therapeutics, Inc. share price will rise to $30.50 per share over the next 12 months.
-
What Do Analysts Say About Bicara Therapeutics, Inc.?
Analysts are divided on their view about Bicara Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bicara Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Bicara Therapeutics, Inc.'s Price Target?
The price target for Bicara Therapeutics, Inc. over the next 1-year time period is forecast to be $30.50 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BCAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bicara Therapeutics, Inc. is a Buy. 8 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BCAX?
You can purchase shares of Bicara Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bicara Therapeutics, Inc. shares.
-
What Is The Bicara Therapeutics, Inc. Share Price Today?
Bicara Therapeutics, Inc. was last trading at $21.43 per share. This represents the most recent stock quote for Bicara Therapeutics, Inc.. Yesterday, Bicara Therapeutics, Inc. closed at $21.47 per share.
-
How To Buy Bicara Therapeutics, Inc. Stock Online?
In order to purchase Bicara Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BCAX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BCAX
Sector
P/E ratio
--
21.37x
PEG ratio
-0.08x
-0.01x
P/B ratio
3.50x
1.72x
Price / LTM sales
--
1.44x
Growth Metrics
BCAX
Sector
Revenue growth
--
3.44%
Earnings growth
-107.22%
14.97%
Revenue (5-year growth)
--
6.27%
Earnings forecast
-$0.65
-$0.22
Profitability
BCAX
Sector
Profitability FY 2025
-$105K
$2.4M
Return on invested capital
-26.37%
-33.43%
Return on assets
-24.8%
-29.45%
Return on equity
-26.44%
-40.29%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
May
12
Estimated Next Earnings Date
Feb
9
Balance Sheet
BCAX
Sector
Total cash
$290.2M
$25.6M
Short term investments
--
$22.7M
Total assets
$529.3M
$70.4M
Long term debt
$880K
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
